Please try another search
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company’s ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
Steven Kelly | 58 | 2023 | President, CEO & Director |
Sanford S. Zweifach | 67 | 2023 | Independent Chairman of the Board |
Regina Hodits | 55 | 2023 | Independent Director |
Nina Bhardwaj | - | 2020 | Member of Scientific Advisory Board |
Briggs W. Morrison | 64 | 2023 | Independent Director |
Padmanee Sharma | - | 2023 | Member of Scientific Advisory Board |
Carl H. June | 70 | - | Member of Scientific Advisory Board |
Lisa M. Coussens | - | - | Member of Scientific Advisory Board |
Saar Gill | - | - | Co-Founder & Chairman of Scientific Advisory Board |
Prasad S. Adusumilli | - | 2020 | Member of Scientific Advisory Board |
Michael Patrick Torok | 45 | 2023 | Independent Director |
Björn Odlander | 66 | 2023 | Independent Director |
Hyam I. Levitsky | 66 | - | Member of Scientific Advisory Board |
Lin Guey | - | 2023 | Member of Scientific Advisory Board |
John A. Hohneker | 64 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review